These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8481545)

  • 1. Is growth hormone associated with diabetic retinopathy?
    Hattori N; Moridera K; Ishihara T; Hino M; Ikekubo K; Kurahachi H
    J Diabetes Complications; 1993; 7(1):12-4. PubMed ID: 8481545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation and clinical applications of measurement of urinary growth hormone in diabetic subjects.
    Suzuki K; Miyata H; Suzuki T; Kajinuma H
    Diabetes; 1989 Dec; 38(12):1567-72. PubMed ID: 2684712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of growth hormone in the development of diabetic retinopathy.
    Alzaid AA; Dinneen SF; Melton LJ; Rizza RA
    Diabetes Care; 1994 Jun; 17(6):531-4. PubMed ID: 8082520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence for increased growth hormone responses to growth hormone-releasing hormone in patients with diabetic retinopathy.
    Pietschmann P; Schernthaner G; Prskavec F; Gisinger C; Freyler H
    Diabetes; 1987 Feb; 36(2):159-62. PubMed ID: 3100367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of diabetic retinopathy with somatostatin analogues].
    Lang GE
    Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Growth hormone response to arginine administration in diabetics--with special reference to the multiple regression analysis in association with diabetic retinopathy].
    Kitada M; Yasuda K; Takeda N; Miura K
    Nihon Naibunpi Gakkai Zasshi; 1989 Jun; 65(6):558-71. PubMed ID: 2792459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary human growth hormone measurement using a highly sensitive sandwich enzyme immunoassay: diagnostic and therapeutic uses in patients with growth hormone deficiency.
    Kohno H; Murakami Y; Kodaira T
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1496-500. PubMed ID: 2229307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients.
    Dong QY; Cui Y; Chen L; Song J; Sun L
    Eur J Ophthalmol; 2008; 18(1):94-8. PubMed ID: 18203092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pharmacological characterization of anomalous metoclopramide-induced growth hormone secretion in insulin-dependent diabetes mellitus.
    Caviezel F; Lepore G; Maglio ML; Croci M; Comi G; Morricone L
    Acta Diabetol Lat; 1989; 26(2):133-45. PubMed ID: 2781979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy.
    Hogeboom van Buggenum IM; Polak BC; Reichert-Thoen JW; de Vries-Knoppert WA; van Hinsbergh VW; Tangelder GJ
    Diabetologia; 2002 Feb; 45(2):203-9. PubMed ID: 11935151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic retinopathy and urinary albumin excretion rate in type II (non-insulin-dependent) diabetic patients.
    Migdalis IN; Hatzigakis SM; Dimakopoulos N; Tolis A; Likoudi A
    J Med; 1996; 27(5-6):341-50. PubMed ID: 9151202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinopathy in type II diabetes mellitus associated with above-normal urinary excretion of RBP.
    Holm J; Nielsen NV; Hemmingsen L
    Kidney Int Suppl; 1994 Nov; 47():S105-8. PubMed ID: 7869657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The urinary concentration of sialic acid is increased in non-insulin-dependent diabetic patients with microangiopathy: a possible useful marker for diabetic microangiopathy.
    Suzuki K; Ishida H; Sugimoto C; Taguchi Y; Matsuda H; Nosaka K; Someya Y; Kadowaki S; Seino Y
    Diabet Med; 1995 Dec; 12(12):1092-6. PubMed ID: 8750219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyrotropin-releasing hormone (TRH) does not suppress growth hormone response to L-dopa in insulin-dependent diabetes mellitus.
    Krassowski J; Jeske W; Zgliczyński S
    Endokrynol Pol; 1992; 43(3):344-8. PubMed ID: 1345575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive therapy with guanfacine induces elevated plasma growth hormone levels in diabetic patients.
    Coves MJ; Gomis R; Casamitjana R; Lienas V; Vilaradell E
    J Med; 1989; 20(3-4):291-6. PubMed ID: 2572660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance and insulin deficiency in diabetic retinopathy of non-insulin-dependent diabetes.
    Maneschi F; Mashiter K; Kohner EM
    Diabetes; 1983 Jan; 32(1):82-7. PubMed ID: 6336706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurements of urinary growth hormone in the assessment of its secretory status.
    Lin MH; Lin DY
    J Formos Med Assoc; 1993 Sep; 92(9):807-11. PubMed ID: 7904863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exaggerated growth hormone response to growth hormone-releasing hormone in type I diabetes mellitus.
    Krassowski J; Felber JP; Rogala H; Jeske W; Zgliczynski S
    Acta Endocrinol (Copenh); 1988 Feb; 117(2):225-9. PubMed ID: 3132790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absent elevations in growth hormone, factor VIII related antigen, and plasminogen activator activity during exercise in diabetic patients resistant to retinopathy.
    Sundkvist G; Lilja B; Almér LO
    Diabetes Res; 1988 Jan; 7(1):25-30. PubMed ID: 3135976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary neutrophil gelatinase-associated lipocalin in type 2 diabetes: Relation to nephropathy and retinopathy.
    Hosny SS; Bekhet MM; Hebah HA; Mohamed NR
    Diabetes Metab Syndr; 2018 Nov; 12(6):1019-1024. PubMed ID: 29960862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.